anti-Ubiquitin+1, mAb (40B3)

CHF 322.00
In stock
YIF-LF-MA0087100 µlCHF 322.00
More Information
Product Details
Synonyms UB+1; Frameshift
Product Type Monoclonal Antibody
Properties
Clone 40B3
Isotype Mouse IgG1 κ
Immunogen/Antigen Synthetic peptide (KLH coupled) corresponding to C-terminal residues of human Ubiquitin +1.
Application

Western Blot (1:500~1,000)
Immunoprecipitation (1~2 μl )

Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS No
Product Specification Sheet
Datasheet Download PDF

Ubiquitin+1 (Ub+1) is a novel mutant form of ubiquitin that can be produced through a process known as molecular frameshift. Ub+1 can be polyubiquitinated to produce aberrant polyubiquitin chains that inhibit the 26S proteasome. Especially ub+1 is accumulated in aggregates containing amyloid-β and phosphorylated-tau. Elevated expression of Ub+1 mRNA and protein has been observed in the brains of patients with Alzheimer's disease. Also ub +1 acts as an aggravating factor in polyglutamine-induced neuro-degeneration. Protein modifier which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Attachment to proteins as a Lys-48-linked polymer usually leads to their degradation by proteasome. Attachment to proteins as a monomer or as an alternatively linked polymer does not lead to proteasomal degradation and may be required for numerous functions, including maintenance of chromatin structure, regulation of gene expression, stress response, ribosome biogenesis and DNA repair.

Product References

1) Van Leeuwen, F.W. et al. (1998) Science, 279, 242-247. (General)
2) Van Leeuwen, F.W. et al. (1998) Trends Neurosci. 21(8), 331-335. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.